Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Minor clone of del(17p) provides a reservoir for relapse in multiple myeloma

3 Aug 2023

Abstract excerpt

The deletion of chromosome 17p (del(17p)) is considered a crucial prognostic factor at the time of diagnosis in patients with multiple myeloma (MM). However, the impact of del(17p) on survival at different clonal sizes at relapse, as well as the patterns of clonal evolution between diagnosis and relapse and their prognostic value, has not been well described. To address these issues, we analyzed the interphase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chromosomal and Genetic Variations
Share to Glycosylation and Glycoproteins Research
Share to Multiple Myeloma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37534514
DOI: 10.3324/haematol.2023.283533

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Minor clone of del(17p) provides a reservoir for relapse in multiple myelomaPMID 37534514Read ↗

del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma.Semantic proximity Read ↗

Prevalence and timing of TP53 mutations in del(17p) myeloma and effect on survivalSemantic proximity Read ↗

Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), gain 1q, hyperdiploidy, and tumor load.Semantic proximity Read ↗

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma.Semantic proximity Read ↗

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factorSemantic proximity Read ↗

Loss of p53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cellsSemantic proximity Read ↗

Pomalidomide plus low-dose dexamethasone in multiple myeloma with deletion 17p and/or translocation (4;14): IFM 2010-02 trial resultsSemantic proximity Read ↗

Cross center single-cell RNA sequencing study of the immune microenvironment in rapid progressing multiple myelomaSemantic proximity Read ↗

Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO Study.Semantic proximity Read ↗

High-Risk Multiple Myeloma: Redefining Risk and Rethinking Therapy.Semantic proximity Read ↗

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high‐risk cytogenetics: IKEMA subgroup analysisSemantic proximity Read ↗

Understanding the role of hyperdiploidy in myeloma prognosis: which trisomies really matter?Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.